Tempus AI (TEM) said Wednesday it entered a multi-year collaboration with Genialis to advance the development and validation of RNA-based biomarker algorithms for cancer treatment.

Financial details weren't disclosed.

Genialis will leverage Tempus' multimodal dataset to validate its AI foundation model, which is based on data from around 1 million RNA-sequencing samples.

Through this partnership, Genialis can now use Tempus' multimodal dataset and analytics platform, Lens, to access de-identified patient records and tools for signature validation, aiding in the market launch of its clinical algorithms.

Tempus, in turn, gains the right to evaluate and potentially license these algorithms for use in its xR platform, the company said.

Shares of Tempus were down 2.1% in recent trading.

Price: 38.06, Change: -0.81, Percent Change: -2.10